DEF: Lite Strategy Sets 2026 Annual Meeting Agenda

Lite Strategy, Inc. announces its virtual 2026 Annual Meeting of Stockholders to vote on director elections, executive compensation, auditor ratification, and a new equity compensation plan.

Summary

• The Annual Meeting of Stockholders will be held virtually on February 12, 2026, at 9:00 a.m. Pacific Time, with a record date of December 15, 2025.
• Key proposals include the election of two directors (Justin J. File and Joshua Riezman), an advisory vote on named executive officer compensation for fiscal year 2025, ratification of CBIZ CPAs as independent auditors, and approval of the 2026 Omnibus Equity Compensation Plan.
• The proposed 2026 Equity Plan aims to authorize 2,000,000 new shares for equity awards, replacing the 2008 Plan, and incorporates governance features such as a $400,000 annual limit for non-employee directors and prohibitions on option repricing without stockholder approval.
• Justin J. File, the current CEO, CFO, and Secretary, is proposed to receive 455,000 stock options at an exercise price of $2.02, vesting over 36 months, contingent on the 2026 Plan's approval.
• The company initiated an evaluation of strategic alternatives on July 22, 2024, which influenced the fiscal year 2025 compensation philosophy to prioritize retention and cash preservation.
• Former executives David M. Urso (President and Chief Executive Officer) and Richard G. Ghalie (Chief Medical Officer) had their employment terminated on August 1, 2024, receiving severance packages and subsequent consulting fees.
• The company reported a net loss of $16 million for fiscal year 2025, with total cash and cash equivalents at $18 million as of June 30, 2025, which was a key performance metric for executive compensation.

Sentiment

Score: 3

Explanation: The filing indicates significant operational challenges, including a net loss, underperforming stock, and a strategic review that could lead to a wind-down. While a new equity plan is proposed, and management is focused on cash preservation, the overall context of executive terminations, underwater options, and compliance issues points to a negative outlook. The capital raise via PIPE and warrants suggests a need for funding, but the overall situation remains precarious.

Positives

• The company is proposing a new 2026 Omnibus Equity Compensation Plan designed to attract, motivate, and retain key talent by aligning their economic interests with stockholders.
• The new equity plan includes strong corporate governance features such as a $400,000 annual compensation limit for non-employee directors, a prohibition on option repricing without stockholder approval, and restrictions on liberal share recycling.
• Management's compensation philosophy for fiscal year 2025 was strategically realigned to focus on cash preservation, which directly benefited shareholders during a period of strategic alternatives review.
• The Board has established a Science Committee to provide expert advice and guidance on drug development technologies and other scientific matters, indicating a commitment to strategic scientific direction.
• The company has implemented an Insider Trading Policy and Anti-Hedging and Pledging Policies to promote compliance with securities laws and responsible stock ownership among its personnel.

Negatives

• All outstanding equity options granted before and during fiscal year 2024 are currently 'underwater' as of the filing date, meaning their exercise price exceeds the fair market value, diminishing their incentive value.
• Two executive officers, David M. Urso and Richard G. Ghalie, had their employment terminated on August 1, 2024, resulting in significant severance payments totaling over $1.1 million combined.
• Joshua Riezman and Dr. Nicholas Glover had delinquent Section 16(a) reports (late Form 3 and Form 4 filings), indicating potential lapses in regulatory compliance.
• The company reported a net loss of $16 million for fiscal year 2025, reflecting ongoing financial challenges.
• Lite Strategy's Total Shareholder Return (TSR) of $26 significantly underperformed the Nasdaq Biotechnology Index TSR of $113 over the period starting June 30, 2022, indicating poor stock performance relative to its industry.
• The company changed its independent registered public accounting firm from Deloitte & Touche LLP to CBIZ CPAs, which, while not explicitly negative, can sometimes signal underlying issues, though no adverse opinion was noted from the previous auditor.

Risks

• The company is currently evaluating strategic alternatives, including potential transactions or an orderly wind-down of operations, which introduces significant uncertainty about its future viability and shareholder value.
• The classified Board structure could potentially deter third-party tender offers or delay stockholders from enacting significant changes to the Board's composition for up to two years.
• The company's ability to attract and retain highly qualified employees, directors, and advisors is crucial, and a failure to provide competitive equity incentives could force increased cash compensation, reducing resources for growth.
• The potential dilution from the proposed 2026 Equity Plan, with a total potential overhang of 9.71%, could be a concern for existing shareholders.
• The fact that existing stock options are underwater may reduce their effectiveness as a retention and incentive tool for employees and management.
• Delinquent Section 16(a) reports for certain directors suggest potential weaknesses in internal controls or oversight regarding regulatory compliance.

Future Outlook

The company's compensation philosophy for fiscal year 2025 was realigned due to an ongoing evaluation of strategic alternatives, including potential transactions or an orderly wind-down of operations, with a goal of maximizing asset value for shareholders. The approval of the 2026 Omnibus Equity Compensation Plan is expected to enable the company to attract, motivate, and retain highly qualified employees, directors, and advisors, which is crucial for future success, especially given the competitive environment. The plan is designed to provide sufficient shares for approximately two to three years of new awards, assuming current grant practices and hiring activity.

Management Comments

• "I look forward to the opportunity to virtually meet with our stockholders." Frederick W. Driscoll, Chair of the Board.
• "On behalf of our employees and Board of Directors, I would like to express our appreciation for our stockholders' continued interest in Lite Strategy, Inc." Frederick W. Driscoll, Chair of the Board.
• "We believe Notice and Access provides stockholders with a convenient method to access the proxy materials and vote, while allowing us to conserve natural resources and reduce the costs of printing and distributing the proxy materials."
• "We believe that our compensation policies and decisions are focused on pay-for-performance principles, aligned with our stockholders interests and consistent with current market practices."
• "Our Board and the Compensation Committee believe that our compensation policies and practices are effective in implementing our compensation philosophy and in helping us achieve our corporate goals."
• "We believe our approach to compensation does not encourage excessive risk-taking by our executives as it is not a market outlier, is based on a typical mix of shortand long-term compensation tied to both internal objectives and to stockholder value and reflects the importance of the retention of our remaining executive employee throughout our strategic alternative phase of operations during fiscal year 2025."
• "We strongly believe that approval of 2026 Plan will enable us to achieve our goals in attracting and retaining our most valuable asset: our employees and other service providers."

Industry Context

The company operates in the life sciences and potentially digital asset/blockchain technology sectors, as indicated by the backgrounds of its directors (e.g., Mr. File's experience in life sciences, Mr. Lee's involvement with Litecoin and blockchain, Mr. Riezman's background in digital asset trading). The peer group for executive compensation consists of publicly traded drug development companies, emphasizing oncology. The company's underperformance in Total Shareholder Return compared to the Nasdaq Biotechnology Index suggests it is lagging behind broader industry trends in the biotech sector. The strategic alternatives review indicates a challenging period, possibly reflecting broader industry pressures or specific company-level issues. The involvement of directors with digital asset expertise suggests a potential pivot or diversification into that space, which is a rapidly evolving and competitive industry.

Comparison to Industry Standards

• Lite Strategy's Total Shareholder Return (TSR) of $26 (assuming $100 invested from June 30, 2022) significantly underperformed the Nasdaq Biotechnology Index (Peer Group TSR) of $113 over the same period, indicating a substantial lag compared to the broader biotechnology industry benchmark.
• The company's executive compensation peer group for fiscal year 2025 consisted of 20 publicly traded drug development companies with a median market cap of $111 million (as of June 2023), generally without material revenue from commercial products and with an emphasis on oncology, including companies like Aeglea BioTherapeutics, Kronos Bio, and Evofem Biosciences, Inc.
• The CEO Pay Ratio of 2.61 to 1 (PEO $912,667 vs. Median Employee $350,117) is relatively low compared to the average CEO-to-worker pay ratio in the S&P 500, which often ranges from 200:1 to 300:1, though Lite Strategy is a smaller company.
• The decision to not grant equity awards to executive officers or employees in fiscal year 2025 due to the strategic alternatives announcement deviates from typical industry practice where equity is a standard component of long-term incentive compensation.

Management Changes

Corporate Governance

Related Party Transactions

• Severance and consulting agreements with former Chief Executive Officer David M. Urso and former Chief Medical Officer Richard G. Ghalie, effective August 1, 2024. Mr. Urso received $614,000 in severance, a pro-rata bonus, PTO benefits, COBRA, and $67,788 in consulting/success fees. Dr. Ghalie received $503,165 in severance, a pro-rata bonus, PTO benefits, COBRA, and $30,472 in consulting/success fees.
• Appointment of Joshua Riezman as a director on August 5, 2025, pursuant to a Side Letter with GSR Strategies LLC, a purchaser in the private investment in public equity (PIPE) on July 22, 2025.
• Advisory Agreement with Green Dragon Investments LLC, where director Charles B. Lee is a beneficiary. Lite Strategy pays Green Dragon a fee in warrants to purchase common stock for asset management services.

Stakeholder Impact

• Shareholders face potential dilution from the proposed 2026 Equity Plan (9.71% total overhang) and significant uncertainty due to the strategic alternatives review, which includes a potential wind-down of operations. The company's underperformance in TSR compared to industry peers is a concern.
• Employees may benefit from the proposed 2026 Equity Plan designed to attract and retain talent through equity incentives, but the ongoing strategic review could lead to job insecurity or operational changes.
• Creditors could be impacted by the strategic alternatives review, including a potential wind-down, which might affect the company's ability to meet its obligations, although cash preservation is a stated goal.
• Management's compensation is tied to performance, particularly cash preservation during the strategic review, and new equity grants are proposed to incentivize the current CEO.

Next Steps

• Stockholders are to vote on director elections, executive compensation, auditor ratification, and the 2026 Omnibus Equity Compensation Plan at the Annual Meeting on February 12, 2026.
• The Board and Compensation Committee intend to consider the results of the advisory Say-on-Pay vote in future executive compensation determinations.
• If the 2026 Equity Plan is approved, it will become effective on February 12, 2026, and no additional grants will be made under the 2008 Plan.
• The Audit Committee will reconsider its selection of audit firms if stockholders fail to ratify CBIZ CPAs, but may decide not to change its selection.
• Stockholders intending to present proposals for the fiscal 2027 annual meeting must submit them by September 1, 2026 (for SEC Rule 14a-8) or between October 15, 2026, and November 14, 2026 (for other proposals).

Key Dates

Recommendation

The filing reveals significant red flags for investors. The company is undergoing a "strategic alternatives" review, explicitly mentioning a "potential orderly wind-down of operations," which signals severe distress and high risk of liquidation. The stock has drastically underperformed its biotech peers (TSR of $26 vs. Nasdaq Biotech Index $113), and all existing options are "underwater." While a new equity plan is proposed, the context is one of a company struggling for survival, not growth. Executive terminations with substantial severance packages, a net loss of $16 million, and compliance issues (late SEC filings) further underscore the precarious financial and operational health. The focus on cash preservation as the primary performance metric for the CEO in FY2025, rather than growth or profitability, reinforces the defensive posture. Given the high risk of a wind-down and severe underperformance, a seasoned investor would likely recommend selling to minimize further losses.

Keywords

Proxy Statement, Annual Meeting, Executive Compensation, Equity Plan, Stock Options, Corporate Governance, Director Election, Auditor Ratification, Strategic Alternatives, Biotechnology, Financial Reporting, SEC Filing, Lite Strategy